Diffusion Pharmaceuticals Inc
NASDAQ:DFFN
Intrinsic Value
Diffusion Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. [ Read More ]
The intrinsic value of one
DFFN
stock under the Base Case scenario is
7.35
USD.
Compared to the current market price of 9.25 USD,
Diffusion Pharmaceuticals Inc
is
Overvalued by 21%.
Diffusion Pharmaceuticals Inc's market capitalization is 18.9m USD.
DFFN stock price is 9.25 USD.
DFFN stock (7.35 USD) is 21% less than its price (9.25 USD).
DFFN. Open Relative Valuation
DFFN has upside potential of 332% compared to the average analyst price target.
Open Wall St Estimates
DFFN has negative Free Cash Flow for the last twelve months.
DFFN's ROE (Return on Equity) has significantly decreased in the last 3 years from -51% to -64%, and is approaching profitability.
DFFN has negative Operating Income for the last twelve months.
DFFN has negative Net Income for the last twelve months.
DFFN's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -180% to 6 244%.
DFFN's ROE (Return on Equity) for the past 12 months is negative and is equal to -64%.
DFFN's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 6 244%.
DFFN has negative three-year average ROE (Return on Equity): -62%. The company is not efficient at transforming stockholders' equity into net income.
DFFN has negative three-year average ROIC (Return on Invested Capital): -54 157%. The company is not efficient at using invested capital to generate operating income.
DFFN's short-term assets (16m USD) exceed its short-term liabilties (1m USD).
DFFN's long-term assets (16m USD) exceed its long-term liabilties (1m USD).
DFFN's D/E (Debt to Equity) is very low and is equal to 0.
DFFN's Altman Z-Score is very low and is equal to -12.3.
Valuation Backtest
Diffusion Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
DFFN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Diffusion Pharmaceuticals Inc
Balance Sheet Decomposition
Diffusion Pharmaceuticals Inc
| Current Assets | 15.7m |
| Cash & Short-Term Investments | 15m |
| Other Current Assets | 695.1k |
| Current Liabilities | 1.5m |
| Accounts Payable | 932.4k |
| Accrued Liabilities | 532.6k |
Earnings Waterfall
Diffusion Pharmaceuticals Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-13.7m
USD
|
|
Operating Income
|
-13.7m
USD
|
|
Other Expenses
|
650.9k
USD
|
|
Net Income
|
-13.1m
USD
|
Free Cash Flow Analysis
Diffusion Pharmaceuticals Inc
DFFN Profitability Score
Profitability Due Diligence
Diffusion Pharmaceuticals Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
Diffusion Pharmaceuticals Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
DFFN Solvency Score
Solvency Due Diligence
Diffusion Pharmaceuticals Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Diffusion Pharmaceuticals Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DFFN Price Targets Summary
Diffusion Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
DFFN
is 40 USD
.
Ownership
DFFN Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
DFFN Price
Diffusion Pharmaceuticals Inc
| Average Annual Return | -20.67% |
| Standard Deviation of Annual Returns | 90.51% |
| Max Drawdown | -99% |
| Market Capitalization | 18.9m USD |
| Shares Outstanding | 2 040 020 |
| Percentage of Shares Shorted | 0.12% |
Company Profile
Diffusion Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Diffusion Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Charlottesville, Virginia and currently employs 16 full-time employees. The company went IPO on 2016-11-09. Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development of therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed. The Company’s product candidate, Trans Sodium Crocetinate (TSC), is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. The firm is focused on the development of TSC for the treatment of hypoxia and as a platform to enhance standard-of-care treatment for conditions complicated by hypoxia with a particular near-term focus on hypoxic solid tumors. Hypoxia is associated with the pathophysiology of many acute and chronic conditions including cancers, heart attack, stroke, ARDS, skin and soft tissue diseases, neurodegenerative diseases and other intractable and difficult-to-treat conditions, further complicating treatment of the underlying condition by medical providers.
Contact
IPO
Employees
Officers
The intrinsic value of one
DFFN
stock under the Base Case scenario is
7.35
USD.
Compared to the current market price of 9.25 USD,
Diffusion Pharmaceuticals Inc
is
Overvalued by 21%.
You don't have any saved screeners yet
